Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

BRCA1/BRCA2 mutation carriers often undergo risk-reducing salpingo-oophorectomy (RRSO) before natural menopause, raising the issue of hormonal replacement treatment (HRT) use. There is conflicting evidence on the effect of HRT on breast cancer (BC) risk, and there are limited data on risk based on age at exposure. In the general population, HRT users have an increased BC risk (hazard ratio = 1.34). We assessed the impact of short-term HRT use on BC risk among healthy BRCA1/2 mutation carriers, with emphasis on age at exposure to HRT.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur J Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): May 2021

Volume: 148

Affiliations

[1 ] Department of Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel; Medical Genetics Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Israel. Electronic address: rachelmc@szmc.org.il.

[2 ] Faculty of Medicine, Hebrew University of Jerusalem, Israel.

[3 ] Department of Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel.

[4 ] Department of Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Israel; In Vitro Fertilization Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

[5 ] Department of Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel; Medical Genetics Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

[6 ] Medical Genetics Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

[7 ] Medical Genetics Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Israel.

[8 ] Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel; Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Article

Publisher Item ID: S0959-8049(21)00089-7

DOI: 10.1016/j.ejca.2021.02.007

PubMed ID: 33743487

SO-VID: 9e6cc8dc-3d1f-404e-9279-ed3cd2bb17c7

History

Keywords: Cancer risk,Risk-reducing salpingo-oophorectomy,Oestrogen replacement therapy,Menopause,Invasive breast cancer,Hormone replacement therapy,Hereditary cancer,Ductal carcinoma in situ (DCIS),Combined oestrogen and progesterone,BRCA mutation carriers

Data availability:

Keywords: Cancer risk, Risk-reducing salpingo-oophorectomy, Oestrogen replacement therapy, Menopause, Invasive breast cancer, Hormone replacement therapy, Hereditary cancer, Ductal carcinoma in situ (DCIS), Combined oestrogen and progesterone, BRCA mutation carriers

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 8

See all cited by